PURPOSE: To evaluate the efficacy and safety of a flexible regimen with intravitreal injections of ranibizumab in @entity1 with naive @entity1940 secondary to age-related @entity1020 and to determine whether the final outcome is related to the number of injections. METHODS: Prospective, noncomparative, consecutive case series study. We included 90 eyes of 88 @entity1 that were initially treated with 3 consecutive monthly intravitreal injections of ranibizumab, and thereafter, follow-up visits were progressively spread out to a maximum of 8 weeks apart in the absence of visual acuity loss and signs of lesion activity. The primary end points were changes in visual acuity (Early Treatment @entity6 Study letters), foveal thickness measured by spectral-domain optical coherence tomography, and @entity75 ( @entity75 ) measured by @entity941 angiography. RESULTS: The median visual acuity improved from 53 letters at baseline to 60 letters at Month 1 (P < 0.0001), 63 letters at Month 3 (P < 0.0001), and 60 letters at Month 12 (P < 0.0001). A significant reduction was also observed in foveal thickness and @entity75 (P < 0.0001). The mean number of injections was 4.4, and the mean number of visits was 8.0. Treatment consisted of 3 injections for 40% of @entity1 , and 60% of @entity1 received more than 3 injections. No significant association was observed between the visual acuity improvement and the number of injections. No relevant side effects were observed. CONCLUSION: A flexible regimen with ranibizumab therapy is efficacious and safe in @entity1 with neovascular age-related @entity1020 , reducing both the burden of injections and follow-up visits. The visual acuity improvement was independent of the number of injections.

One-year results of a flexible regimen with ranibizumab therapy in XXXX : relationship with the number of injections.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1940 :: ('MESH:D020256', 'Disease') :: ['choroidal neovascularization'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetic Retinopathy'] @entity75 :: ('MESH:D001927', 'Disease') :: ['lesion size', 'LS'] @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['macular degeneration']
@entity1020 :: (MESH:D008268,Disease) :: ['macular degeneration']
